AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36482520
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of glucosyl hesperidin per day
Trial: 36482520
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of glucosyl hesperidin per day
Trial: 32739495
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Anakinra (100 mg daily for 14 days), Pentoxifylline (400 mg three times a day for 28 days), and Zinc sulfate (220 mg orally once daily for 6 months)
Trial: 32739495
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapy including Methylprednisolone (32 mg orally once daily for 28 days)
Trial: 32365232
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment rules (ITRs) using information from electronic health records (EHRs)
Trial: 35432984
Drug: Colchicine add
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine add on treatment (1 mg daily for 7 days, then 0.5 mg daily for another 7 days)
Trial: 35432984
Drug: Colchicine add
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine add on treatment
Trial: 35765796
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) treatment
Trial: 32816626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of olive fruit extract (7.5 mg HT) and almond skin extracts (210 mg ASPs)
Trial: 32356027
Drug: Vaginal probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal probiotic gel with L. plantarum YUN‐V2.0, L. pentosus YUN‐V1.0 and L. rhamnosus YUN‐S1.0 for 10 consecutive days
Trial: 32356027
Drug: Vaginal probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal probiotic gel
Trial: 32356027
Drug: Women needing
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women needing rescue treatment
Trial: 34218922
Drug: Mixed tocopherols
RxNorm normalized name: vitamin E (as mixed tocopherols)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed tocopherols (TMIX) at 0, 5, 10, or 15 mg/kg of BW daily
Trial: 36354032
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose mRNA-1273 (100 μg)
Trial: 36354032
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose mRNA-1273 (2×100 μg)
Trial: 36354032
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil discontinuation (mycophenolate mofetil-)
Trial: 36354032
Drug: Local adverse
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local adverse events after single and double dose mRNA-1273
Trial: 33245043
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (mometasone furoate 0.1%) plus dummy narrowband ultraviolet B light
Trial: 33245043
Drug: Narrowband ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband ultraviolet B light (plus placebo topical corticosteroids)
Trial: 33245043
Drug: Combination (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (topical corticosteroids plus narrowband ultraviolet B light)
Trial: 35122097
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day of MCTs at breakfast
Trial: 35122097
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day of MCTs at dinnertime (positive control group)
Trial: 32232954
Drug: Family focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family focused therapy for individuals at CHR (6 months)
Trial: 32232954
Drug: Family psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family psychoeducational treatment (6 months)
Trial: 32232954
Drug: Matched controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched controls (no specific treatment mentioned)
Trial: 35015247
Drug: Asynchronous binocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asynchronous binocular treatment using 3D movies with amblyopic eye stimulated first for 10.5 hours over <3 weeks
Trial: 35015247
Drug: Asynchronous binocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asynchronous binocular treatment
Trial: 35900031
Drug: Test nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test nilotinib capsule (200 mg)
Trial: 35900031
Drug: Reference nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference nilotinib capsule (200 mg)
Trial: 33000503
Drug: Tralokinumab 300
RxNorm normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 300 mg every 2 weeks (Q2W) plus topical corticosteroids (TCS) as needed
Trial: 32398441
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with 1.0 ppm DEX (1.8 μg)
Trial: 32398441
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with 2.0 ppm DEX (3.6 μg)
Trial: 32398441
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with 1:80,000 adrenaline (22.5 μg)
Trial: 34087418
Drug: Glycopyrrolate bolus
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate bolus (0.4 mg IV)
Trial: 34087418
Drug: Titrated glycopyrrolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated glycopyrrolate (0.01 mg IV every 3 min as needed)
Trial: 34406656
Drug: Add-on cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on cannabidiol (CBD) titrated from 2.5 to 20 mg/kg/day, with potential increase to 30 mg/kg/day based on response and tolerance.
Trial: 34406656
Drug: Add-on cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on cannabidiol (CBD) treatment
Trial: 34794220
Drug: Irinotecan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan plus S‐1 (intravenous infusion of irinotecan 160 mg/m(2) on day 1 and oral S‐1 80‐120 mg on days 1‐10, repeated every 14 days)
Trial: 32183057
Drug: Total protein
RxNorm normalized name: Total Protein Reagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total protein intake of 1 g·Kg−1·d−1 in week 2
Trial: 34001723
Drug: Aprocitentan (dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan (dual endothelin-receptor antagonist)
Trial: 34001723
Drug: Moderately dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately dosed angiotensin-converting enzyme inhibitor
Trial: 34750747
Drug: PPV-guided fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV-guided fluid therapy
Trial: 34750747
Drug: CVP-guided fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVP-guided fluid therapy
Trial: 34019245
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus platinum-based chemotherapy
Trial: 34019245
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus platinum-based chemotherapy with PD-L1 expression of at least 5%
Trial: 35007480
Drug: Nicotine-replacement therapies
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine-replacement therapies (NRT)
Trial: 32534843
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg preoperatively
Trial: 34701521
Drug: HA-IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-IMRT with memantine for salvage treatment in MRI surveillance group
Trial: 33663100
Drug: Edaravone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone treatment on top of conventional treatment
Trial: 34918875
Drug: Metopimazine (MPZ)
RxNorm normalized name: metopimazine
DrugBank: Metopimazine (DB13591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metopimazine (MPZ) 60 mg
Trial: 32981872
Drug: Decision making
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decision making by oral and maxillofacial surgeons (OMFSs)
Trial: 34863618
Drug: Factors associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors associated with vaccine deliberation and reluctance
Trial: 34863618
Drug: Trend in
RxNorm normalized name: TITANIUM DIOXIDE 24 mg in 1 mL / ZINC OXIDE 58.2 mg in 1 mL TOPICAL CREAM [TRENDY JOHN SPF-32 Sheer Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trend in vaccine acceptance
Trial: 35227528
Drug: Fiber-reinforced glass-ionomer
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber-reinforced glass-ionomer cement (GIC) with adhesive treatment
Trial: 35227528
Drug: Fiber-reinforced glass-ionomer
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber-reinforced glass-ionomer cement (GIC) without adhesive treatment
Trial: 35227528
Drug: Conventional glass-ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glass-ionomer cement (GIC) with adhesive treatment
Trial: 35227528
Drug: Resin-modified glass-ionomer
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin-modified glass-ionomer cement (GIC) with adhesive treatment
Trial: 35227528
Drug: Conventional glass-ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glass-ionomer cement (GIC) without adhesive treatment
Trial: 35227528
Drug: Resin-modified glass-ionomer
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin-modified glass-ionomer cement (GIC) without adhesive treatment
Trial: 35753316
Drug: Fractional doses
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional doses of RTS,S/AS01E (Fx012-14)
Trial: 35753316
Drug: Rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies vaccine (control group)
Trial: 35753316
Drug: Full doses
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full doses of RTS,S/AS01E (R012-20)
Trial: 35753316
Drug: Full doses
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full doses of RTS,S/AS01E (R012-14)
Trial: 35753316
Drug: Fractional doses
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional doses of RTS,S/AS01E (Fx017-20)
Trial: 32052032
Drug: Vehicle (rate-matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (rate-matched infusion)
Trial: 36159932
Drug: Jin's three-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin's three-needle therapy (JTNT)
Trial: 35788240
Drug: Cognitive Functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Functional Therapy (CFT) intervention, 5 to 7 sessions based on clinical progression.
Trial: 32829703
Drug: Mumps-specific IgG
RxNorm normalized name: mumps virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mumps-specific IgG antibody testing using Enzygnost anti-parotitis IgG enzyme immunoassay
Trial: 34783839
Drug: Background medication-based
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background medication-based individualized comparator (enalapril, valsartan, or placebo)
Trial: 34783839
Drug: Background medication-based
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background medication-based individualized comparator
Trial: 33044196
Drug: Active antidepressants
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antidepressants (fluoxetine, duloxetine, paroxetine, sertraline)
Trial: 33938432
Drug: Combination serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination serum containing galactomyces ferment filtrate (GFF), dexpanthenol, and Centella asiatica, administered as three drops twice daily for 8 weeks.
Trial: 33938432
Drug: Combination serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination serum containing GFF, dexpanthenol, and C. asiatica
Trial: 36115638
Drug: Emotion Regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion Regulation Therapy for Caregivers (ERT-C)
Trial: 36115638
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Caregivers (CBT-C)
Trial: 34535197
Drug: TPX-100 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPX-100 (200 mg)
Trial: 34414904
Drug: Resveratrol 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 500 mg a day with meloxicam 15 mg a day for 90 days
Trial: 34414904
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with meloxicam 15 mg a day for 90 days
Trial: 32245343
Drug: Median Urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median Urinary Iodine Concentration (MUI) measured in 1997, 1999, 2011, 2014, and 2017 with values of 228 µg/L, 214 µg/L, 1826 µg/L, 171 µg/L, and 183 µg/L respectively.
Trial: 32245343
Drug: Median Thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median Thyroid Volume (MTvol) measured in 1997, 1999, 2011, 2014, and 2017 with values of 2.9 mL, 1.2 mL, 2.4 mL, 1.0 mL, and 1.8 mL, and 2.8 mL respectively.
Trial: 35751161
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) at a daily dose of 600 mg orally in combination with other antiretrovirals (ARVs)
Trial: 34567245
Drug: Secondary cytoreduction
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary cytoreduction and HIPEC (Cisplatin 75 mg/m2 43°C over 60 minutes)
Trial: 33189262
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (BBP, MBP, HAL)
Trial: 39718172
Drug: Monthly sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulfadoxine-pyrimethamine
Trial: 36090567
Drug: 80:40 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80:40 group (80 mg/kg/day ARA and 40 mg/kg/day DHA)
Trial: 36090567
Drug: 120:60 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120:60 group (120 mg/kg/day ARA and 60 mg/kg/day DHA)
Trial: 34609956
Drug: Asynchronous Video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asynchronous Video Observed Treatment (aVOT)
Trial: 36385690
Drug: Nitrate containing
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate containing beetroot juice (400 mg daily)
Trial: 36385690
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg daily)
Trial: 32293830
Drug: Tetris and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetris and therapy (EMDR)
Trial: 32293830
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (therapy only - EMDR)
Trial: 36449490
Drug: Real data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real data example regarding tablet absorption rate and extent
Trial: 32926850
Drug: 15% dextrose
RxNorm normalized name: Clinimix Sulfite Free, Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% dextrose injection (D15W)
Trial: 36125874
Drug: Group F
RxNorm normalized name: Prostaglandin group F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group F (ferrule preparation)
Trial: 33154023
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with 16,000 IU of calcifediol per week
Trial: 33154023
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to usual asthma treatment
Trial: 32043561
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (OT) behavioral intervention
Trial: 35807854
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of whey protein microgel
Trial: 35807854
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg mulberry leaf extract with a complete 510 kcal meal
Trial: 33877019
Drug: Intravenous urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urokinase
Trial: 33574437
Drug: Midazolam intravenous
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam intravenous sedation
Trial: 32085836
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg S44819 twice a day
Trial: 32085836
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg S44819 twice a day
Trial: 36174812
Drug: Standard boric
RxNorm normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard boric acid solution
Trial: 32857445
Drug: Varenicline directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline directly observed therapy (DOT)
Trial: 32857445
Drug: Varenicline self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline self-administered therapy (SAT)
Trial: 35465733
Drug: trastuzumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab + chemotherapy (eribuline, capecitabine, or vinorelbine)
Trial: 35788754
Drug: AI-based ultra-low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI-based ultra-low-dose contrast medium (ULDCM)
Trial: 35788754
Drug: Low-dose contrast
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose contrast medium (LDCM)
Trial: 35788754
Drug: Ultra-low-dose contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose contrast medium (ULDCM)
Trial: 32212508
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of Shuxuetong (SXT)
Trial: 35045869
Drug: Meclofenamate (MFA)
RxNorm normalized name: meclofenamate
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate (MFA) combined with standard dose Temozolomide (TMZ)
Trial: 35045869
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose Temozolomide (TMZ)
Trial: 34661548
Drug: Tablet PC
RxNorm normalized name: PCS-499
DrugBank: PCS-499 (DB15122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet PC
Trial: 34661548
Drug: Tablet PC
RxNorm normalized name: PCS-499
DrugBank: PCS-499 (DB15122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet PC and Smart Glasses
Trial: 32703613
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control group (unplugged pulsed 30 minutes of shortwave therapy)
Trial: 32730628
Drug: iv acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv acetaminophen
Trial: 35371287
Drug: CNHM model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNHM model during bladder perfusion treatment
Trial: 32380271
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) administered at weeks 0, 2, and 6
Trial: 32380271
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline control) administered at weeks 0, 2, and 6
Trial: 35786572
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures retained by one implant
Trial: 35786572
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures retained by two implants
Trial: 32916128
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg